University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Pelin Cinar, MD, MS

Pelin Cinar, MD, MS

Medical Director of Quality and Safety, UCSF Helen Diller Family Comprehensive Cancer Center; Clinical Asst. Professor, Dept. of Gastrointestinal Oncology, UCSF

Cancer Center Program Memberships

Cancer Control

Research Summary

Dr. Pelin Cinar is a specialist in gastrointestinal oncology with a particular interest in pancreatic cancer. As director of quality improvement for the UCSF Helen Diller Family Comprehensive Cancer Center, she is committed to developing projects to ensure that each oncology patient at UCSF receives superior care.

Cinar earned her medical degree and completed her residency in internal medicine at the University of California, Irvine School of Medicine. She received her fellowship training in hematology and oncology at UCSF, where she was appointed chief fellow. During her fellowship, she became passionate about quality improvement in health care and participated in efforts to improve care for oncology patients.

In 2014, Cinar joined the faculty of the Stanford Department of Medicine as a gastrointestinal oncologist. She was also assistant medical director for cancer care quality and associate director for quality and curriculum for Stanford's oncology fellowship program. In 2015, she was selected to participate in the American Society of Clinical Oncology's Quality Training Program.

Education

University of California at Irvine, B.A., 06/2000, Anthropology
University of California at Irvine, B.S., 06/2000, Biological Sciences: Specialization in Physiology
University of California at Irvine, M.S., 06/2002, Environmental Health Science & Policy: Specialization in Epidemiology
UC Irvine School of Medicine, M.D., 06/2007, Doctor of Medicine
UC Irvine School of Medicine, 06/2010, Resident Physician
UCSF Medical Center, 06/2013, Hematology and Oncology Fellow
UCSF Medical Center, 01/2014, Hematology and Oncology Chief Fellow
American Society of Clinical Oncology (ASCO), 10/2015, ASCO Quality

Honors & Awards

  • 2014
    Educational Travel Award, Mount Zion Health Fund
  • 2013
    Appointed as the Chief Fellow, UC San Francisco Hematology/Oncology Fellowship Program
  • 2012
    Selected as a Participant, 2012 AACR / ASCO Workshop: Methods in Clinical Cancer Research
  • 2012
    Educational Travel Award, Mount Zion Health Fund
  • 2008
    The David K. Litke, MD Memorial Intern of the Year Award, UC Irvine Department of Internal Medicine Residency Program
  • 2007
    Department of Medicine Award, UC Irvine School of Medicine
  • 2006
    Inducted into Gold Humanism Honor Society, UC Irvine School of Medicine
  • 2006
    Associated Medical Student Government (AMSG) Community Service Award, UC Irvine School of Medicine
  • 2005
    Outstanding Student / Resident Research Poster Award, “Medical Student Run Community Service Promoting Smoking Prevention in Orange County, CA Middle Schools” Western Group on Educational Affairs
  • 2004
    Nominated for AMSG Community Service Award, UC Irvine School of Medicine
  • 2000
    Initiated as a member of School of Biological Sciences Scholastic Honor Society, University of
    California at Irvine
  • 2000
    Initiated in Lambda Alpha Kappa, National Collegiate Honor Society for Anthropology, University of California at Irvine
  • 1999
    Summer Fellowship Award, American Cancer Society, Orange County Region
  • 1999
    Excellence in Research Poster Award, University

Selected Publications

  1. Sugalski J, Franco T, Shulman LN, Cinar P, Bachman J, Crews JR, Olsen M, Schatz A, Kubal T. Creative Strategies Implemented During the Coronavirus Pandemic That Will Impact the Future of Cancer Care. J Natl Compr Canc Netw. 2020 Oct 30; 1-5.
    View on PubMed
  2. Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS. Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign? CA Cancer J Clin. 2020 Sep 30.
    View on PubMed
  3. Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020 Aug 05; JCO2001364.
    View on PubMed
  4. Cinar P, Cox J, Kamal A, Bickel K, Krzyzanowska M, Armitage J, Ganti AK, Ward J, Wong S, Lonial S, Bosserman L. Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes. JCO Oncol Pract. 2020 08; 16(8):431-434.
    View on PubMed
  5. Cinar P, Kubal T, Freifeld A, Mishra A, Shulman L, Bachman J, Fonseca R, Uronis H, Klemanski D, Slusser K, Lunning M, Liu C. Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe. J Natl Compr Canc Netw. 2020 04 15; 1-6.
    View on PubMed
  6. Gonzalez A, Walker EJ, Van Loon K, Cinar P, Atreya CE. Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series. Anticancer Res. 2020 02; 40(2):865-871.
    View on PubMed
  7. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol. 2019 12; 42(12):898-902.
    View on PubMed
  8. Borno HT, Bakke BM, Kaplan C, Hebig-Prophet A, Chao J, Kim YJ, Yeager J, Cinar P, Small E, Boscardin C, Gonzales R. A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot Feasibility Stud. 2019; 5:123.
    View on PubMed
  9. Wick EC, Cinar P. Variation Across the Continuum of Surgical Oncology Care. JAMA Netw Open. 2018 10 05; 1(6):e183035.
    View on PubMed
  10. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 11; 211(5):1010-1019.
    View on PubMed
  11. Cinar P, Ko AH. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. Chin Clin Oncol. 2017 Jun; 6(3):29.
    View on PubMed
  12. Cinar P, Calkins SM, Venook AP, Kelley RK. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer Res. 2014 Dec; 34(12):7357-60.
    View on PubMed
  13. Cinar P, Ko AH. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2014 Feb; 12(2):167-72.
    View on PubMed
  14. Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):653-64.
    View on PubMed
  15. Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008 Jan 01; 26(1):66-75.
    View on PubMed

Go to UCSF Profiles, powered by CTSI